These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2455612)

  • 1. Discordance between concentrations of prostate-specific antigen and acid phosphatase in serum of patients with adenocarcinoma of the prostate.
    Beaver TR; Schultz AL; Fink LM; Andersen CA; Donohue RE
    Clin Chem; 1988 Jul; 34(7):1524. PubMed ID: 2455612
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
    Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
    [No Abstract]   [Full Text] [Related]  

  • 3. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology.
    Panteghini M; Pagani F; Bonora R
    Eur J Clin Chem Clin Biochem; 1992 Mar; 30(3):135-9. PubMed ID: 1376155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the "hook effect".
    Vaidya HC; Wolf BA; Garrett N; Catalona WJ; Clayman RV; Nahm MH
    Clin Chem; 1988 Oct; 34(10):2175-7. PubMed ID: 2458866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of prostate-specific antigen and prostatic acid phosphatase concentrations in serum before and 1-42 days after transurethral resection of the prostate and orchidectomy.
    Price A; Attwood SE; Grant JB; Gray TA; Moore KT
    Clin Chem; 1991 Jun; 37(6):859-63. PubMed ID: 1710953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for adenocarcinoma of the prostate.
    Miles BJ
    Henry Ford Hosp Med J; 1989; 37(1):5-7. PubMed ID: 2475458
    [No Abstract]   [Full Text] [Related]  

  • 8. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
    Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
    Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour markers in monitoring the treatment of advanced prostate cancer.
    Cooper EH; Armitage TG
    Prog Clin Biol Res; 1990; 359():65-72; discussion 73-4. PubMed ID: 1704634
    [No Abstract]   [Full Text] [Related]  

  • 10. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
    Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
    Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1984 Jul; 132(1):58-60. PubMed ID: 6726962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marker substances and prostate cancer.
    Huber PR
    Urol Res; 1984; 12(5):231-2. PubMed ID: 6083651
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged.
    Jenkins D; Jones RT; Clarke AM
    Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
    Barak M; Mecz Y; Lurie A; Gruener N
    J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
    Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
    J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nondetectable prostate-specific antigen in moderately differentiated adenocarcinoma of prostate.
    Daugherty RL; Cos LR; Keller JW; di Sant'Agnese A
    Urology; 1992 Jun; 39(6):552-5. PubMed ID: 1377434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of various manipulations on serum phosphatase levels in benign disease.
    Greene FT; Thompson IM
    J Urol; 1974 Aug; 112(2):232-6. PubMed ID: 4135604
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
    Mortarelli EA
    Ann Clin Lab Sci; 1992; 22(4):201-6. PubMed ID: 1380223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical assessment of prostate cancer staging.
    Graham SD
    Cancer; 1992 Jul; 70(1 Suppl):269-74. PubMed ID: 1376195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
    Pagani F; Zambolin T; Bonora R; Panteghini M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.